This technology is an anticancer composition containing a rectangular metallacycle compound as an active ingredient, self-assembled from ruthenium and iridium metal clips using pyridine-functionalized BODIPY fluorescent dye as a ligand. It targets lung, breast, cervical, and brain cancers and includes health functional food applications.
Commonly used platinum-based anticancer drugs like cisplatin have side effects such as nephrotoxicity and issues with drug resistance or dependency upon repeated administration. While ruthenium-iridium supramolecular complexes have been studied as alternatives, there have been no cases using BODIPY-based linkers, and it has been difficult to directly track where the drug acts within cancer cells.
This technology uses ruthenium and iridium instead of platinum to selectively inhibit cancer cell proliferation, showing higher antiproliferative activity than cisplatin. Depending on the linker structure, it can be designed to selectively kill breast or brain cancer cells. The BODIPY core allows for real-time intracellular localization via confocal microscopy. It can be applied to non-platinum anticancer drug development, fluorescence-based drug tracking, and targeted therapies for brain and breast cancer, expanding into a theranostic platform that enables simultaneous treatment and visual monitoring of drug distribution.
N/A
